Patents by Inventor Mahdi Fawzi
Mahdi Fawzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7838027Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.Type: GrantFiled: September 30, 2004Date of Patent: November 23, 2010Assignee: Wyeth LLCInventors: Sripriya Venkata Ramana Rao, Syed M. Shah, Hanumantharao Tatapudy, Richard William Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon A. Hasan
-
Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
Patent number: 7605257Abstract: Processes are described for preparing 42-pegylated rapamycins including reacting a rapamycin with an acylating agent in the presence of a lipase to form an acylated rapamycin and reacting the acylated rapamycin with a methoxy poly(ethylene glycol) derivative in the presence of a base. Also described are processes for preparing 32-pegylated tacrolimus and/or ascomycin using these steps.Type: GrantFiled: March 5, 2007Date of Patent: October 20, 2009Assignee: WyethInventors: Jianxin Gu, Mark Ruppen, Tianmin Zhu, Mahdi Fawzi -
Patent number: 7553498Abstract: A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the subcoat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.Type: GrantFiled: March 30, 2007Date of Patent: June 30, 2009Assignee: WyethInventors: Sripriya Venkata Ramana Rao, Syed M. Shah, Hanumantharao Tatapudy, Richard William Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon A Hasan
-
Patent number: 7550153Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose(hypromellose) and water.Type: GrantFiled: March 30, 2007Date of Patent: June 23, 2009Assignee: WyethInventors: Sripriya Venkata Ramana Rao, Syed M. Shah, Hanumantharao Tatapudy, Richard William Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon A Hasan
-
Patent number: 7544370Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a distintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.Type: GrantFiled: September 30, 2004Date of Patent: June 9, 2009Assignee: WyethInventors: Sripriya Venkata Ramana Rao, Syed M. Shah, Hanumantharao Tatapudy, Richard William Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon A. Hasan
-
Publication number: 20080070975Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.Type: ApplicationFiled: August 3, 2007Publication date: March 20, 2008Applicant: WyethInventors: Syed Shah, Christian Ofslager, Mahdi Fawzi, Natalyia Bazhina
-
Publication number: 20070254876Abstract: The present invention provides a salt form, and compositions thereof, useful as a modulator of one or more GPCRs and which exhibits desirable characteristics for the same. The present invention also provides methods for preparing said salt form.Type: ApplicationFiled: September 12, 2006Publication date: November 1, 2007Applicant: WyethInventors: Subodh Deshmukh, Kadum Ali, Christopher Diorio, Eric Ehrnsperger, Mahdi Fawzi, Syed Shah, Mahmoud Mirmehrabi
-
Publication number: 20070243244Abstract: Disclosed herein are methods of treating at least one bacterial infection, such as lower gastrointestinal infections, comprising orally administering a pharmaceutical composition comprising tigecycline. The composition can take solid or liquid forms, such as solutions, dispersions, or solid forms comprising tigecycline having at least one enteric coating.Type: ApplicationFiled: December 21, 2006Publication date: October 18, 2007Inventors: Syed Shah, Mahdi Fawzi
-
Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
Publication number: 20070212371Abstract: Processes are described for preparing 42-pegylated rapamycins including reacting a rapamycin with an acylating agent in the presence of a lipase to form an acylated rapamycin and reacting the acylated rapamycin with a methoxy poly(ethylene glycol) derivative in the presence of a base. Also described are processes for preparing 32-pegylated tacrolimus and/or ascomycin using these steps.Type: ApplicationFiled: March 5, 2007Publication date: September 13, 2007Applicant: WyethInventors: Jianxin Gu, Mark Ruppen, Tianmin Zhu, Mahdi Fawzi -
Publication number: 20070196443Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose(hypromellose) and water.Type: ApplicationFiled: March 30, 2007Publication date: August 23, 2007Applicant: WyethInventors: Sripriya Ramana Rao, Syed Shah, Hanumantharao Tatapudy, Richard Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon Hasan
-
Publication number: 20070196444Abstract: A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the subcoat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.Type: ApplicationFiled: March 30, 2007Publication date: August 23, 2007Applicant: WyethInventors: Sripriya Ramana Rao, Syed Shah, Hanumantharao Tatapudy, Richard Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon Hasan
-
Publication number: 20070059366Abstract: The present invention provides sustained-release formulations useful and methods for using the same.Type: ApplicationFiled: September 12, 2006Publication date: March 15, 2007Applicant: WyethInventors: Kadum Ali, Christopher Diorio, Eric Ehrnsperger, Mahdi Fawzi, Syed Shah
-
Publication number: 20070060580Abstract: The present invention provides salt forms, and compositions thereof, useful as modulators of one or more GPCRs and which exhibit desirable characteristics for the same.Type: ApplicationFiled: September 12, 2006Publication date: March 15, 2007Applicant: WyethInventors: Subodh Deshmukh, Kadum Ali, Christopher Diorio, Wendy Dulin, Eric Ehrnsperger, Mahdi Fawzi, Syed Shah
-
Publication number: 20070042033Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.Type: ApplicationFiled: September 30, 2004Publication date: February 22, 2007Applicant: WyethInventors: Sripriya Venkata Ramana Rao, Syed Shah, Hanumantharao Tatapudy, Richard Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Suwon Hasan
-
Publication number: 20070026080Abstract: Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion.Type: ApplicationFiled: June 16, 2006Publication date: February 1, 2007Applicant: WyethInventors: Gurmukh Chanana, Dominic Ventura, Richard Saunders, Mahdi Fawzi
-
Publication number: 20070015824Abstract: Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.Type: ApplicationFiled: July 13, 2006Publication date: January 18, 2007Applicant: WyethInventors: Syed Shah, Mahdi Fawzi, Eric Ehrnsperger, Panolil Raveendranath
-
Publication number: 20070015791Abstract: Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.Type: ApplicationFiled: July 13, 2006Publication date: January 18, 2007Applicant: WyethInventors: Syed Shah, Mahdi Fawzi, Panolil Raveendranath, Eric Ehrnsperger
-
Publication number: 20070015828Abstract: Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.Type: ApplicationFiled: July 13, 2006Publication date: January 18, 2007Applicant: WyethInventors: Syed Shah, Eric Ehrnsperger, Richard Saunders, Mahdi Fawzi, Rocco Galante, Garth Whiteside
-
Publication number: 20070014859Abstract: An oral, highly bioavailable unit dosage form of O-desmethylvenlafaxine succinate (DVS) having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours is described. In one embodiment, the superbioavailable DVS composition has a delayed release of about two hours and a total release of greater than about 95% within about 12 to about 14 hours. Use of the formulation in treating depression and reducing the gastrointestinal side-effects of O-desmethylvenlafaxine (ODV) is also described.Type: ApplicationFiled: July 13, 2006Publication date: January 18, 2007Applicant: WyethInventors: Syed Shah, Mahdi Fawzi, Christopher Diorio
-
Publication number: 20060247181Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.Type: ApplicationFiled: March 13, 2006Publication date: November 2, 2006Inventors: Mahdi Fawzi, Tianmin Zhu, Syed Shah